Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1α in human colon carcinoma: Impact of ESM-1 on prognosis and its correlation with clinicopathological features

Oncology Reports

Volumn 28, Issue 5, 2012, Pages 1701-1708

  Kim, Joo Heon ^a   Park, Mee Young ^a   Kim, Chang Nam ^a   Kim, Kyo Hyun ^a   Kang, Ho Bum ^b   Kim, Kwang Dong ^c   Kim, Jae Wha ^b  

^a Eulji University School of Medicine   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Gyeongsang National University   (South Korea)

Author keywords

Colon cancer; Endothelial cell specific molecule 1; HIF 1 ; Hypoxia; Immunohistochemistry

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIAL CELL SPECIFIC MOLECULE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEOGLYCAN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL FEATURE; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR VOLUME;

CELL HYPOXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROTEOGLYCANS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84866457822     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2012     Document Type: Article

References (49)

1. Cannito S, Novo E, Compagnone A, et al: Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 29: 2267-2278, 2008.
2. Lluis JM, Buricchi F, Chiarugi P, Morales A and Fernandez-Checa JC: Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-{kappa}B via c-SRC and oxidant-dependent cell death. Cancer Res 67: 7368-7377, 2007. (Pubitemid 47206567)
3. Sansone P, Piazzi G, Paterini P, et al: Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells. J Cell Mol Med 13: 3876-3887, 2009.
4. To KK, Koshiji M, Hammer S and Huang LE: Genetic instability: the dark side of the hypoxic response. Cell Cycle 4: 881-882, 2005. (Pubitemid 41359750)
5. Huang LE, Bindra RS, Glazer PM and Harris AL: Hypoxia-induced genetic instability - a calculated mechanism underlying tumor progression. J Mol Med 85: 139-148, 2007. (Pubitemid 46188219)
6. Bristow RG and Hill RP: Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8: 180-192, 2008. (Pubitemid 351301853)
7. Yoo YG, Hayashi M, Christensen J and Huang LE: An essential role of the HIF-1alpha-c-Myc axis in malignant progression. Ann NY Acad Sci 1177: 198-204, 2009.
8. Huang LE, Arany Z, Livingston DM and Bunn HF: Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259, 1996. (Pubitemid 26422262)
9. Maynard MA and Ohh M: The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 64: 2170-2180, 2007. (Pubitemid 350103108)
10. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
11. Brahimi-Horn MC, Chiche J and Pouyssegur J: Hypoxia and cancer. J Mol Med 85: 1301-1307, 2007. (Pubitemid 50004093)
12. Brahimi-Horn MC and Pouyssegur J: Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem 43: 165-178, 2007.
13. Brahimi-Horn MC, Chiche J and Pouyssegur J: Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19: 223-229, 2007. (Pubitemid 46386401)
14. Brahimi-Horn MC and Pouyssegur J: HIF at a glance. J Cell Sci 122: 1055-1057, 2009.
15. Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A and Sivridis E: Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 22: 25-30, 2005. (Pubitemid 41185858)
16. Sivridis E, Giatromanolaki A and Koukourakis MI: Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. J Clin Pathol 58: 1033-1038, 2005. (Pubitemid 41416051)
17. Giles RH, Lolkema MP, Snijckers CM, et al: Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene 25: 3065-3070, 2006. (Pubitemid 43780471)
18. Koukourakis MI, Giatromanolaki A, Polychronidis A, et al: Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Sci 97: 582-588, 2006. (Pubitemid 44056605)
19. Lassalle P, Molet S, Janin A, et al: ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 271: 20458-20464, 1996. (Pubitemid 26281817)
20. Sarrazin S, Adam E, Lyon M, et al: Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765: 25-37, 2006. (Pubitemid 41752939)
21. Bechard D, Scherpereel A, Hammad H, et al: Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 167: 3099-3106, 2001. (Pubitemid 32852547)
22. Bechard D, Meignin V, Scherpereel A, et al: Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 37: 417-425, 2000.
23. Scherpereel A, Depontieu F, Grigoriu B, et al: Endocan, a new endothelial marker in human sepsis. Crit Care Med 34: 532-537, 2006. (Pubitemid 43145635)
24. Grigoriu BD, Depontieu F, Scherpereel A, et al: Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12: 4575-4582, 2006. (Pubitemid 44297807)
25. Abid MR, Yi X, Yano K, Shih SC and Aird WC: Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 72: 136-145, 2006. (Pubitemid 44767770)
26. Leroy X, Aubert S, Zini L, et al: Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology 56: 180-187, 2010.
27. Aitkenhead M, Wang SJ, Nakatsu MN, Mestas J, Heard C and Hughes CC: Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta) ig-h3, and NrCAM. Microvasc Res 63: 159-171, 2002. (Pubitemid 34971632)
28. Song Q, Jing H, Wu H, Zhou G, Kajiyama T and Kambara H: Gene expression analysis on a photodiode array-based bioluminescence analyzer by using sensitivity-improved SRPP. Analyst 135: 1315-1319, 2010.
29. Maurage CA, Adam E, Mineo JF, et al: Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 68: 633-641, 2009.
30. Kang YH, Ji NY, Lee CI, et al: ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids 40: 1003-1013, 2010.
31. Ji NY, Kim YH, Jang YJ, et al: Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer. Cancer Sci 101: 2248-2253, 2010.
32. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
33. Chen LY, Liu X, Wang SL and Qin CY: Over-expression of the endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. J Int Med Res 38: 498-510, 2010.
34. Rennel E, Mellberg S, Dimberg A, et al: Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 313: 1285-1294, 2007. (Pubitemid 46509777)
35. Bechard D, Gentina T, Delehedde M, et al: Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 276: 48341-48349, 2001.
36. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987. (Pubitemid 17064313)
37. Hockel M and Vaupel P: Biological consequences of tumor hypoxia. Semin Oncol 28: 36-41, 2001. (Pubitemid 32522236)
38. Foo SS, Abbott DF, Lawrentschuk N and Scott AM: Functional imaging of intratumoral hypoxia. Mol Imaging Biol 6: 291-305, 2004. (Pubitemid 39263636)
39. Mabjeesh NJ and Amir S: Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 22: 559-572, 2007. (Pubitemid 46647268)
40. Filep JG: Endocan or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis? Crit Care Med 34: 574-575, 2006.
41. Sarrazin S, Lyon M, Deakin JA, et al: Characterization and binding activity of the chondroitin/dermatan sulfate chain from endocan, a soluble endothelial proteoglycan. Glycobiology 20: 1380-1388, 2010.
42. Zuo L, Zhang SM, Hu RL, et al: Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol 14: 4562-4568, 2008.
43. Ryan HE, Poloni M, McNulty W, et al: Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60: 4010-4015, 2000. (Pubitemid 30636574)
44. Swami M: Hypoxia: the HIF2alpha puzzle. Nat Rev Cancer 10: 603, 2010.
45. Gu YZ, Moran SM, Hogenesch JB, Wartman L and Bradfield CA: Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7: 205-213, 1998. (Pubitemid 28527216)
46. Kietzmann T, Cornesse Y, Brechtel K, Modaressi S and Jungermann K: Perivenous expression of the mRNA of the three hypoxia-inducible factor alpha-subunits, HIF1alpha, HIF2alpha and HIF3alpha, in rat liver. Biochem J 354: 531-537, 2001. (Pubitemid 32269716)
47. Clottes E: Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy. Bull Cancer 92: 119-127, 2005 (In French).
48. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
49. Baba Y, Nosho K, Shima K, et al: HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 176: 2292-2301, 2010.